174 related articles for article (PubMed ID: 36228155)
21. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
22. Genetic characterisation of sarcomatoid carcinomas reveals multiple novel actionable mutations and identifies
Ding Y; Shao Y; Na C; Yin JC; Hua H; Tao R; Jiang Y; Hu R; He X; Miao C; Zhu D; Zhang Z
J Med Genet; 2022 Jan; 59(1):10-17. PubMed ID: 33115932
[TBL] [Abstract][Full Text] [Related]
23. Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers.
Shaib WL; Zakka K; Staley C; Roberts A; Akce M; Wu C; Alese OB; El-Rayes BF
Oncologist; 2020 May; 25(5):414-421. PubMed ID: 31784493
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological features and CCT2 and PDIA2 expression in gallbladder squamous/adenosquamous carcinoma and gallbladder adenocarcinoma.
Zou Q; Yang ZL; Yuan Y; Li JH; Liang LF; Zeng GX; Chen SL
World J Surg Oncol; 2013 Jun; 11():143. PubMed ID: 23782473
[TBL] [Abstract][Full Text] [Related]
25. Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations.
Narayan RR; Creasy JM; Goldman DA; Gönen M; Kandoth C; Kundra R; Solit DB; Askan G; Klimstra DS; Basturk O; Allen PJ; Balachandran VP; D'Angelica MI; DeMatteo RP; Drebin JA; Kingham TP; Simpson AL; Abou-Alfa GK; Harding JJ; O'Reilly EM; Butte JM; Matsuyama R; Endo I; Jarnagin WR
Cancer; 2019 Feb; 125(4):575-585. PubMed ID: 30427539
[TBL] [Abstract][Full Text] [Related]
26. Serial analysis of gene expression identifies connective tissue growth factor expression as a prognostic biomarker in gallbladder cancer.
Alvarez H; Corvalan A; Roa JC; Argani P; Murillo F; Edwards J; Beaty R; Feldmann G; Hong SM; Mullendore M; Roa I; Ibañez L; Pimentel F; Diaz A; Riggins GJ; Maitra A
Clin Cancer Res; 2008 May; 14(9):2631-8. PubMed ID: 18451226
[TBL] [Abstract][Full Text] [Related]
27. Genomic Characterization of
Mondaca S; Razavi P; Xu C; Offin M; Myers M; Scaltriti M; Hechtman JF; Bradley M; O'Reilly EM; Berger MF; Solit DB; Li BT; Abou-Alfa GK
JCO Precis Oncol; 2019; 3():. PubMed ID: 32923849
[TBL] [Abstract][Full Text] [Related]
28. Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice.
Lin J; Dong K; Bai Y; Zhao S; Dong Y; Shi J; Shi W; Long J; Yang X; Wang D; Yang X; Zhao L; Hu K; Pan J; Sang X; Wang K; Zhao H
Ann Transl Med; 2019 Sep; 7(18):467. PubMed ID: 31700903
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive genomic profiling and prognostic analysis of cervical gastric-type mucinous adenocarcinoma.
Lu S; Shi J; Zhang X; Kong F; Liu L; Dong X; Wang K; Shen D
Virchows Arch; 2021 Nov; 479(5):893-903. PubMed ID: 33817764
[TBL] [Abstract][Full Text] [Related]
30. Clinical and genetic determinants of ovarian metastases from colorectal cancer.
Ganesh K; Shah RH; Vakiani E; Nash GM; Skottowe HP; Yaeger R; Cercek A; Lincoln A; Tran C; Segal NH; Reidy DL; Varghese A; Epstein AS; Sonoda Y; Chi D; Guillem J; Temple L; Paty P; Hechtman J; Shia J; Weiser M; Aguilar JG; Kemeny N; Berger MF; Saltz L; Stadler ZK
Cancer; 2017 Apr; 123(7):1134-1143. PubMed ID: 27875625
[TBL] [Abstract][Full Text] [Related]
31. High-throughput screening identified miR-7-2-3p and miR-29c-3p as metastasis suppressors in gallbladder carcinoma.
Lu K; Feng F; Yang Y; Liu K; Duan J; Liu H; Yang J; Wu M; Liu C; Chang Y
J Gastroenterol; 2020 Jan; 55(1):51-66. PubMed ID: 31562534
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients.
de Bitter TJJ; de Reuver PR; de Savornin Lohman EAJ; Kroeze LI; Vink-Börger ME; van Vliet S; Simmer F; von Rhein D; Jansen EAM; Verheij J; van Herpen CML; Nagtegaal ID; Ligtenberg MJL; van der Post RS
NPJ Precis Oncol; 2022 Nov; 6(1):83. PubMed ID: 36335173
[TBL] [Abstract][Full Text] [Related]
33. SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K/AKT pathway.
Shu YJ; Weng H; Ye YY; Hu YP; Bao RF; Cao Y; Wang XA; Zhang F; Xiang SS; Li HF; Wu XS; Li ML; Jiang L; Lu W; Han BS; Jie ZG; Liu YB
Mol Cancer; 2015 Jan; 14(1):12. PubMed ID: 25623055
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas.
Lee SM; Sung CO
Sci Rep; 2021 Mar; 11(1):6203. PubMed ID: 33737597
[TBL] [Abstract][Full Text] [Related]
35. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
Botrus G; Kosirorek H; Sonbol MB; Kusne Y; Uson Junior PLS; Borad MJ; Ahn DH; Kasi PM; Drusbosky LM; Dada H; Surapaneni PK; Starr J; Ritter A; McMillan J; Wylie N; Mody K; Bekaii-Saab TS
Oncologist; 2021 Jul; 26(7):569-578. PubMed ID: 33555095
[TBL] [Abstract][Full Text] [Related]
36. Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer.
van Beek EJAH; Hernandez JM; Goldman DA; Davis JL; McLaughlin K; Ripley RT; Kim TS; Tang LH; Hechtman JF; Zheng J; Capanu M; Schultz N; Hyman DM; Ladanyi M; Berger MF; Solit DB; Janjigian YY; Strong VE
Ann Surg Oncol; 2018 Jul; 25(7):2027-2033. PubMed ID: 29725898
[TBL] [Abstract][Full Text] [Related]
37. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
Mirkovic J; McFarland M; Garcia E; Sholl LM; Lindeman N; MacConaill L; Dong F; Hirsch M; Nucci MR; Quick CM; Crum CP; McCluggage WG; Howitt BE
Am J Surg Pathol; 2018 Feb; 42(2):227-233. PubMed ID: 28984674
[TBL] [Abstract][Full Text] [Related]
38. Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes.
Wong W; Lowery MA; Berger MF; Kemel Y; Taylor B; Zehir A; Srinivasan P; Bandlamudi C; Chou J; Capanu M; Varghese A; Yu KH; Iacobuzio-Donahue CA; Shia J; Klimstra DS; Jarnagin WR; Stadler ZK; O'Reilly EM
Cancer; 2019 May; 125(9):1441-1448. PubMed ID: 30620386
[TBL] [Abstract][Full Text] [Related]
39. Role of stratifin (14-3-3 sigma) in adenocarcinoma of gallbladder: A novel prognostic biomarker.
Sirivatanauksorn V; Dumronggittigule W; Dulnee B; Srisawat C; Sirivatanauksorn Y; Pongpaibul A; Masaratana P; Somboonyosdech C; Sripinitchai S; Kositamongkol P; Mahawithitwong P; Tovikkai C; Sangserestid P; Limsrichamrern S
Surg Oncol; 2020 Mar; 32():57-62. PubMed ID: 31751820
[TBL] [Abstract][Full Text] [Related]
40. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
